ACADIA Pharmaceuticals Inc.
ACADAcadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Drugs in Pipeline
13
Phase 3 Programs
7
Upcoming Catalysts
2
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
How ACAD's past catalysts played out
Carbetocin
Hyperphagia in Prader-Willi Syndrome
pimavanserin tartrate
Parkinson's Disease Psychosis
Pimavanserin
Agitation and Aggression in Alzheimer's Disease
ACP-204
Lewy Body Dementia Psychosis
Trofinetide
Rett Syndrome
Pimavanserin tartrate (ACP-103)
Parkinson's Disease Psychosis
Pimavanserin 34 mg
Dementia-related Psychosis
Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]
Autism Spectrum Disorder
ACP-103
Hallucinations
ACP-104
Schizophrenia
ACP-211
Major Depressive Disorder (MDD)
Active drug: pimavanserin 17mg (2 strength tablets)
Parkinson Disease
ACP-044 Dose A
Acute Postoperative Pain
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Carbetocin | Phase 3 | Hyperphagia in Prader-Willi Syndrome | - | - |
pimavanserin tartrate | Phase 3 | Parkinson's Disease Psychosis | - | - |
Pimavanserin | Phase 3 | Agitation and Aggression in Alzheimer's Disease | - | - |
ACP-204 | Phase 3 | Lewy Body Dementia Psychosis | - | - |
Trofinetide | Phase 3 | Rett Syndrome | - | - |
Pimavanserin tartrate (ACP-103) | Phase 3 | Parkinson's Disease Psychosis | - | - |
Pimavanserin 34 mg | Phase 3 | Dementia-related Psychosis | - | - |
Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID] | Phase 2 | Autism Spectrum Disorder | - | - |
ACP-103 | Phase 2 | Hallucinations | - | - |
ACP-104 | Phase 2 | Schizophrenia | - | - |
ACP-211 | Phase 2 | Major Depressive Disorder (MDD) | - | - |
Active drug: pimavanserin 17mg (2 strength tablets) | Phase 2 | Parkinson Disease | - | - |
ACP-044 Dose A | Phase 2 | Acute Postoperative Pain | - | - |
Parkinson's Disease Psychosis
2 drugs in this indication
Acute Postoperative Pain
1 drug in this indication
Agitation and Aggression in Alzheimer's Disease
1 drug in this indication
Rett Syndrome
1 drug in this indication
Hallucinations
1 drug in this indication
Schizophrenia
1 drug in this indication
Lewy Body Dementia Psychosis
1 drug in this indication
Hyperphagia in Prader-Willi Syndrome
1 drug in this indication
Adjunctive Treatment of Major Depressive Disorder
1 drug in this indication
Dementia-related Psychosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ACADIA Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 13 drug candidates in ACADIA Pharmaceuticals Inc.'s (ACAD) pipeline across Phase 3, Phase 2. Its lead program is Carbetocin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ACADIA Pharmaceuticals Inc.'s next FDA catalyst?→
ACADIA Pharmaceuticals Inc.'s (ACAD) next tracked catalyst is a Phase 2 expected January 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACAD biotech catalysts?→
Add ACAD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ACADIA Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.